# A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

> **NCT03307915** · PHASE1 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 25 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **BIOLOGICAL:** Ad26.Mos4.HIV
- **BIOLOGICAL:** MVA-Mosaic
- **BIOLOGICAL:** Clade C gp140 + Mosaic gp140
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03307915
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2021-11-05
- **Final completion:** 2021-11-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03307915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03307915, "A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03307915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*